Skip to main content

Advertisement

Table 1 Demographic, anthropometric and clinical characteristics of the study population number

From: Disease activity and low physical activity associate with number of hospital admissions and length of hospitalisation in patients with rheumatoid arthritis

General demographics    
  Males (n= 70) Females (n= 174) Total
   Physical activity (MET-minutes/week) 1,674.5 (982.5 to 2,479.2) 1,470.0 (993.0 to 2,082.5) 1,550 (989.5 to 2,175.0)
   Age (years) 62.1 (55.8 to 68.7) 62.3 (52.8 to 70.2) 62.1 (53.8 to 69.4)
   Smoking status    
   current smokers n (%) 14 (20.9%) 31 (18.1%) 45 (18.9%)
Anthropometric    
   Height (cm) 172.9 ± 7.1 160.7 ± 6.9* 164.2 ± 8.8
   Weight (kg) 81.7 (73.1 to 93.0) 70.8 (61.6 to 81.3)** 73.8 (64.9 to 84.0)
   Body Mass Index (kg/m2) 27.1 (25.0 to 30.3) 26.7 (24.1 to 31.7) 27.0 (24.4 to 30.8)
   Fat-free mass (kg) 58.6 (53.1 to 65.4) 43.4 (39.1 to 46.9)** 45.9 (41.4 to 53.1)
   Fat mass (%) 28.6 (22.2 to 31.8 38.8 (34.6 to 43.1)** 36.2 (29.7 to 40.8)
RA characteristics    
General characteristics    
   Rheumatoid factor positive n (%) 45 (72.6%) 118 (77.1%) 163 (75.8%)
   Disease duration (years) 9.0 (3.5 to 18.0) 11.0 (4.0 to 20.0) 11.0 (4.0 to 19.0)
Disease activity    
   C-Reactive protein (mg/L) 11.5 (6.0 to 22.2) 8.0 (5.0 to 20.0) 9.0 (5.0 to 21.0)
   ESR (mm/1 hr) 23.0 (5.0 to 39.0) 22.0 (12.2 to 39.0) 23.0 (10.0 to 39.0)
   Disease activity score 28 4.3 ± 1.4 4.2 ± 1.5 4.2 ± 1.4
Disability    
   Health assessment Questionnaire 1.2 (0.5 to 2.1) 1.5 (0.5 to 2.1) 1.5 (0.5 to 2.1)
Medication    
   DMARDs n (%) 65 (92.9%) 144 (83.2%)* 209 (86%)
   Methotrexate n (%) 41 (58.6%) 95 (54.9%) 136 (56%)
   antiTNFα n (%) 6 (8.6%) 24 (13.9%) 30 (12.3%)
   leflunomide n (%) 1 (1.4%) 10 (5.8%) 11 (4.5%)
   prednisolone n (%) 30 (42.9%) 51 (29.5%) 81 (33.3%)
   NSAID n (%) 16 (22.9%) 30 (17.3%) 46 (18.9%)
   Cholesterol-lowering n (%) 16 (22.9%) 28 (16.2%) 44 (18.1%)
  1. Results expressed as number (percentages), median (interquartile range) or mean ± SD as appropriate.
  2. ESR, erythrocyte sedimentation rate, DMARDs, disease modifying anti rheumatic drugs, NSAID, non-steroid anti-inflammatory drugs